LNDC Landec Corp.

Lifecore Biomedical to Participate in Upcoming Investor Conferences

Lifecore Biomedical to Participate in Upcoming Investor Conferences

CHASKA, Minn, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in two upcoming investor conferences. Details regarding Lifecore’s participation are as follows:

  • Jefferies 2025 Global Healthcare Conference – London

Details: Paul Josephs, Lifecore’s president and chief executive officer, will deliver a corporate presentation and Lifecore management will participate in investor meetings

Conference Dates: November 17-20, 2025

Presentation Time/Date: 9:30 – 9:55 a.m. Greenwich Mean Time (4:30 – 4:55 a.m. Eastern Time) on Tuesday, November 18, 2025, webcast available

Location: London, UK

  • Stephens Annual Investment Conference

Details: Mr. Josephs will be a featured speaker in a fireside chat and Lifecore management will participate in 1-on-1 meetings

Conference Dates: November 18-20, 2025

Fireside Chat Time/Date: 9:00 – 9:45 a.m. Central Time on Thursday, November 20, 2025, webcast available

Location: Nashville

Webcasts of the Jefferies presentation and the Stephens fireside chat may be accessed via a link on Lifecore’s investor website on the Investor Events & Presentations page at: . Additionally, replays of the webcasts will be available on the Lifecore website following the conference.

About Lifecore Biomedical

Lifecore Biomedical, Inc. (Nasdaq: ) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at .





Lifecore Biomedical, Inc. Contact Information:

Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
 

Tim Brons (Media)
415-675-7402
 

Ryan D. Lake (CFO)
Lifecore Biomedical
952-368-6244
EN
11/11/2025

Underlying

LNDCLandec Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Landec Corp.

 PRESS RELEASE
Free
LNDC LANDEC CORP.

Lifecore Biomedical to Participate in Upcoming Investor Conferences

Lifecore Biomedical to Participate in Upcoming Investor Conferences CHASKA, Minn, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in two upcoming investor conferences. Details regarding Lifecore’s participation are as follows: Jefferies 2025 Global Healthcare Conference – London Details: Paul Josephs, Lifecore’s president and chief executive officer, will deliver a corporate presentation and Lifecore management will parti...

8h / 50m 1 EN
 PRESS RELEASE
Free
LNDC LANDEC CORP.

Lifecore Biomedical Reports Financial Results for the Three Months End...

Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update -- Recorded $31.1 Million in Revenue During the Three Months Ended September 30, 2025, Representing a 26% Increase From Comparable Period of 2024 -- -- Multiple New Programs Signed with New Customers -- -- Continued Improvements in Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development an...

November 6, 2025 1 EN
 PRESS RELEASE
Free
LNDC LANDEC CORP.

Lifecore Biomedical to Report Financial Results for the Three Months E...

Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025 Webcast Scheduled for Thursday, November 6 at 4:30 p.m. Eastern CHASKA, Minn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the three months ended September 30, 2025, on Thursday, November 6, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore’s senior management team ...

October 30, 2025 1 EN
 PRESS RELEASE
Free
LNDC LANDEC CORP.

Lifecore Biomedical Selected as New Commercial Manufacturing Partner b...

Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product Represents Second Agreement Signed with Same Major Multinational Organization in Recent Months Separate Pre-Clinical Formulation Development Agreement Signed with New Early-Stage Biotech Customer CHASKA, Minn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manuf...

October 29, 2025 1 EN
 PRESS RELEASE
Free
LNDC LANDEC CORP.

Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-...

Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and PolyPeptide Laboratories, Inc. (“PolyPeptide”), a global leader in peptide contract development and manufacturing, today announced the signing of a collaboration agreement aimed at providing an integrated, end-to-end solution for peptide-based pharmaceutical custom...

October 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch